---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-198392"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:06:27.249271+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Taysha reports Q2 net loss $20.9M, cash $172.7M; TSHA-102 high dose data in 1H 2025

## Summary
- Net loss narrowed to $20.9M ($0.09/share) from $24.6M ($0.38/share) in Q2 2023.
- Cash $172.7M at June 30; runway extended into Q4 2026 after $76.8M public offering.
- TSHA-102 low dose data showed durable improvements and no SAEs/DLTs in adult and pediatric trials.
- High dose cohort dosing started; safety/efficacy data from both REVEAL trials expected 1H 2025.

## SEC filing metadata
- accession: 0001193125-24-198392
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312524198392/0001193125-24-198392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312524198392/d760391d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-198392
- JSON: https://secwatch.observer/filing/0001193125-24-198392.json
- Plain text: https://secwatch.observer/filing/0001193125-24-198392.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.